30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

ApiFix to Close $5MM Funding -

ApiFix is slated to close a $5MM round of Series B funding by the end of 2016. Aesculap, a division of B. Braun, is investing $2.8MM in the round. Proceeds will support FDA submission and expansion of clinical and commercial activities in Europe.

The ApiFix® system for correction of Adolescent Idiopathic Scoliosis is CE Mark approved and has reached a 100-patient milestone that was announced in late 3Q16.

The minimally invasive ApiFix procedure does not require fusion. First patients who received the implant are now at four years post-op. In 2015, the company reported that results from 1- to 3-year follow-up in 50 adolescent scoliosis patients treated with ApiFix revealed substantial curve correction and no implant failure. 

Sources: The Trendlines Group Ltd. and B. Braun; ORTHOWORLD Inc. 

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.